Exploring the Benefits and Limitations of Besremi, Jakafi, and Rusfertide in Polycythemia Vera Treatment
Polycythemia Vera Treatment Landscape Jakafi (Ruxolitinib) , developed by Incyte, is an FDA-approved drug for the treatment of Polycythemia Vera . Jakafi is a JAK1/JAK2 inhibitor that works by reducing the overactive signaling of JAK1 and JAK2, which are associated with the symptoms of Polycythemia Vera . Jakafi’s patent expiration date is in 2027, but several companies have filed for generics. However, there might be a delay in the entry of generics due to legal disputes. PharmaEssentia’s new entrant, entry into NCCN guidelines, insights on pricing, and launches Besremi (Ropeginterferon alfa-2b) is a new entrant in the Polycythemia Vera market , developed by PharmaEssentia. It is a subcutaneous injection and has a different mode of action than Jakafi. Besremi is an interferon alpha-2b derivative that regulates the immune system and bone marrow, which can help control the overproduction of blood cells in Polycythemia Vera . Besremi was approved in the EU in 2020 and received FD...